New hope for hard-to-treat amyloidosis patients with prior drug exposure
NCT ID NCT04270175
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tests whether adding daratumumab to pomalidomide and dexamethasone can improve complete remission rates in people with light chain amyloidosis whose disease has returned or not responded after prior daratumumab treatment. About 15 adults with measurable disease who have already received daratumumab will receive the three-drug combination. The goal is to see if this approach works better than historical results with just two drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston University Medical Center
Boston, Massachusetts, 02118, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Weill Cornell Medicine - Multiple Myeloma Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.